ClinicalTrials.gg
Status unknownNCT04457856Updated Aug 3, 2022

A Study of TJ003234 in Rheumatoid Arthritis Patients

A Phase 1 interventional study of TJ003234 injection in Rheumatoid Arthritis, sponsored by I-Mab Biopharma US Limited. Status unknown at 5 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-08-03.

Sponsored by I-Mab Biopharma US Limited · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Aug 2022), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
63
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 249 studies in Arthritis, Rheumatoid with a site in China — 63 open to participants now, 72 under way, 3 of them phase 3. Arthritis, Rheumatoid · China.

Planned enrollment
149th of 217
63 · median 134
Started
2020
with 7 others
Phase 1
54 of 249
20 open now
Registered
122nd of 249
by date

Among the 249 studies in Arthritis, Rheumatoid with a site in China, this one is the 149th largest by planned enrollment of the 217 interventional ones that give a count, is one of 8 that started in 2020, is one of 54 in phase 1, and was the 122nd registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

63 of the 249 studies in Arthritis, Rheumatoid with a site in China are open now. Recruiting first, the newest first:

58 more — sign in →

All 63 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 249 studies in Arthritis, Rheumatoid with a site in China, or all of them as a file.
02

Study summary

Study Purpose and Design: A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Ascending Dose and Multiple Ascending Doses of TJ003234 in Rheumatoid Arthritis Patients.

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • Rheumatoid Arthritis
  • biologics
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must be ≥ 18 and ≤70 years old when signing the , with no limitation of gender.
  • Established Rheumatoid arthritis patients, diagnosed by ACR/EULAR criteria 2010 at least 6 months prior to randomisation.
  • Single Ascending Dose: DAS28 score≤3.2. Multiple Ascending Dose: DAS28 score≤5.1 and >3.2.
  • Allowed one or more standard treatments, but the start date should no later than 12 weeks(84 days) before the randomisation and should take at a stable dose more than 4 weeks(28 days) before the randomisation. The combination taken of Methotrexate (MTX) and leflunomide was not allowed within 4 weeks (28 days) before randomization.
  • Subjects must agree to attendance the study and signed the inform concent by themselves.
  • Subjects(include subjects's wife) are no pregnancy plan during the sceering and 3 months after complete the study and agree to use that protocol suggest.

Exclusion criteria

Exclusion Criteria:

  • Employees of the hospital or any other person that paticipant in the study and their immedidte family members.
  • A documented history of an disease other than RA (other than secondary Sjögren's syndrome) .
  • Previous received Any biologic DMARD therapy including tsDMARD. •A positive (HBsAg, anti-HBc, and/or IgM anti-HBc), or test at screening, indicative of a current or past infection.
  • A history of active tuberculosis (TB) or positive serological test for TB (Quantiferon TB Gold or T-SPOT).
  • Female patients who are pregnant during the study, or are breastfeeding. •, or prior malignancy, with a disease free interval of \<5 years after diagnosis and intervention except curative treatment for basal and squamous cell skin cancer.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
63 participants (estimated)

Study arms

  • Experimental
    TJ003234

    Intravenous administration, single dose (0.3-1-3-10mg/kg) or multiple dose (1-3-6mg/kg, once every week, for 8 weeks) Mode of administration: The investigational drug is administered by intravenous infusion

    Biological: TJ003234 injection

  • Placebo comparator
    Placebo

    Intravenous administration, single dose (0.3-1-3-10mg/kg) or multiple dose (1-3-6mg/kg, once every week, for 8 weeks) Mode of administration: The investigational drug is administered by intravenous infusion

    Biological: TJ003234 injection

Interventions

  • Intravenous administration, single dose (0.3-1-3-10mg/kg) or multiple dose (1-3-6mg/kg, once every week, for 8 weeks)

06

What researchers measure

Primary outcomes

  1. Number of subject with adverse events(AEs)

    Number of subject with adverse events(AEs) to evaluate satety in patient with RA with vital signs, Electrocardiograms, physical examinations, laboratory tests and respiratory-related examinations

    Time frame: First dose up to last follow-up visit (i.e. 90 days after dosing for single dose part, 140 days after first dose for multiple dose part)

Secondary outcomes

  1. AUC from time 0 to the time of the last quantifiable concentration AUC0-tlast of TJ003234

    AUC from time 0 to the time of the last quantifiable concentration AUC0-tlast of TJ003234

    Time frame: Day1 to 90 days after dosing for single dose part, 140 days after for multiple dose part

  2. Maximum observed plasma concentration (Cmax) of TJ003234

    Maximum observed plasma concentration (Cmax) of TJ003234

    Time frame: Day1 to 90 days after dosing for single dose part, 140 days after for multiple dose part

  3. The proportion of subjects who produce anti-drug antibodies

    The proportion of subjects who produce anti-drug antibodies

    Time frame: Day1 to 90 days after dosing for single dose part, 140 days after for multiple dose part

  4. The proportion of subjects who produce neutralizing antibodies

    The proportion of subjects who produce neutralizing antibodies

    Time frame: Day1 to 90 days after dosing for single dose part, 140 days after for multiple dose part

  5. The proportion of subjects who produce the titers of anti-drug antibodies and neutralizing antibodies

    The proportion of subjects who produce the titers of anti-drug antibodies and neutralizing antibodies

    Time frame: Day1 to 90 days after dosing for single dose part, 140 days after for multiple dose part

07

Study locations

5 of 5 sites recruiting
  • The first affiliated hospital of bengbu medical college
    Bengbu, Anhui, China
    Recruiting
  • Peking university people's Hospital
    Beijing, Beijing 10044, China
    Recruiting
  • Nanjing Drum Tower Hospital
    Nanjing, Jiangsu, China
    Recruiting
  • Zhongda Hospital southeast university
    Nanjing, Jiangsu, China
    Recruiting
  • FuDan University shanghai huashan Hospital
    Shanghai, Shanghai, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2020 (actual). Primary completion is estimated for Mar 2023, 31 months after the start.

Of 128 industry-sponsored phase 1 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 32. This study's planned 31 months is above that.

Counting every sponsor, half of 148 studies reached it within 16 months; a quarter within 5 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2020
First posted
Jul 7, 2020
StartActual
Aug 6, 2020
Primary completionEst.
Mar 2023
CompletionEst.
Mar 2023
Last update
Aug 3, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04457856
Lead sponsor
I-Mab Biopharma US Limited
Responsible party
Sponsor
First posted
Jul 7, 2020
Start date
Aug 6, 2020
Primary completion
Mar 2023 (estimated)
Completion
Mar 2023 (estimated)
Last update
Aug 3, 2022

Study contacts

Zhanguo Li
Contact
li99@bjmu.edu.cn
+86010-88326666
yingchao Zhou
Contact
yingchao.zhou@i-mabbiopharma.com
+86010-56176269

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Plonmarlimab

Start the discussion